CGEM Cullinan Oncology Inc
- Stocks
- Healthcare
- NASDAQ: CGEM
Price (delayed)
$7.64
Market cap
$451.33M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.98
Enterprise value
$380.03M
Cullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s strategy is to build
Highlights
The debt has declined by 44% year-on-year and by 17% since the previous quarter
CGEM's quick ratio has plunged by 66% YoY and by 15% from the previous quarter
CGEM's net income is down by 45% YoY and by 16% from the previous quarter
Key stats
What are the main financial stats of CGEM
Market
Valuations
Earnings
Shares outstanding
59.07M
Market cap
$451.33M
Enterprise value
$380.03M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.92
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$234.7M
Net income
-$206.76M
EBIT
-$206.65M
EBITDA
-$206.34M
Free cash flow
-$171.53M
Per share
Balance sheet
Liquidity
EPS
-$2.98
EPS diluted
-$2.98
Free cash flow per share
-$2.91
Book value per share
$8.34
Revenue per share
$0
TBVPS
$8.82
Total assets
$520.33M
Total liabilities
$28.18M
Debt
$1.52M
Equity
$492.15M
Working capital
$247.85M
Debt to equity
0
Current ratio
9.83
Quick ratio
9.46
Net debt/EBITDA
0.35
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-35.2%
Return on equity
-36.9%
Return on invested capital
-42.6%
Return on capital employed
-42%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CGEM stock price
How has the Cullinan Oncology stock price performed over time
Intraday
5.09%
1 week
-3.05%
1 month
-0.78%
1 year
-53.1%
YTD
-37.27%
QTD
1.46%
Financial performance
How have Cullinan Oncology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$234.7M
Net income
-$206.76M
Gross margin
N/A
Net margin
N/A
CGEM's net income is down by 45% YoY and by 16% from the previous quarter
The operating income has contracted by 28% YoY and by 12% from the previous quarter
Price vs fundamentals
How does CGEM's price correlate with its fundamentals
Growth
What is Cullinan Oncology's growth rate over time
Valuation
What is Cullinan Oncology stock price valuation
P/E
N/A
P/B
0.92
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is down by 24% year-on-year and by 15% since the previous quarter
The price to book (P/B) is 34% lower than the 5-year quarterly average of 1.4 and 16% lower than the last 4 quarters average of 1.1
Cullinan Oncology's equity has decreased by 25% YoY and by 11% from the previous quarter
Efficiency
How efficient is Cullinan Oncology business performance
The company's return on assets fell by 29% YoY and by 24% QoQ
Cullinan Oncology's return on equity has decreased by 28% YoY and by 24% QoQ
CGEM's return on invested capital is down by 23% since the previous quarter and by 14% year-on-year
Dividends
What is CGEM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CGEM.
Financial health
How did Cullinan Oncology financials performed over time
CGEM's quick ratio has plunged by 66% YoY and by 15% from the previous quarter
The current ratio has dropped by 66% year-on-year and by 15% since the previous quarter
The debt is 100% smaller than the equity
The debt has declined by 44% year-on-year and by 17% since the previous quarter
Cullinan Oncology's equity has decreased by 25% YoY and by 11% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.